Eisai's breast cancer drug extends lives: Study | world | Hindustan Times
Today in New Delhi, India
Sep 22, 2017-Friday
-°C
New Delhi
  • Humidity
    -
  • Wind
    -

Eisai's breast cancer drug extends lives: Study

Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said on Sunday.

world Updated: Jun 06, 2010 21:34 IST

Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said on Sunday.

The results of the Phase III trial, presented to a meeting of the American Society of Clinical Oncology in Chicago, should change practice, conference organizers told reporters.